{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:12:09Z","timestamp":1780665129072,"version":"3.54.1"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["Data collection was undertaken independently by Ad"],"award-info":[{"award-number":["Data collection was undertaken independently by Ad"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer's Disease Reports"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prevalence of Alzheimer's disease (AD) is rising in China. Although disease-modifying treatments are available, their efficacy is mostly seen in the early stage. Timely and accurate diagnosis is crucial for AD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to describe the diagnostic trajectory, current treatments, and care burden for mild cognitive impairment (MCI)\/AD in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were derived from the Adelphi Real World Dementia Disease Specific Programme\u2122, a cross-sectional survey of neurologists, patients with MCI\/AD dementia and their care partners, conducted in China from February\u2013May 2024. Patient characteristics, diagnoses, treatments, and care were reported by neurologists and supplemented by self-reports from patients and care partners.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 93 neurologists reported on 774 patients. Of patients with a Mini-Mental State Examination (MMSE) score at the time of survey (n\u2009=\u2009699), mean (standard deviation) age was 69.3 (8.2) years, 49.6% (n\u2009=\u2009347) female and most had MCI\/mild AD (MMSE 20\u201328) at survey (52.5%, n\u2009=\u2009367). Over one-third of patients presented with moderate to severe disease at initial consultation (34.7%, n\u2009=\u2009203) and at diagnosis (36.2%, n\u2009=\u2009265). Biomarker testing was infrequently used in diagnosis, with cerebrospinal fluid being the most used (11.2%, n\u2009=\u200981) and physician-reported challenges including cost, patient reluctance, and availability. Most patients received only non-professional care primarily from a partner\/spouse and\/or children, who spent up to 47.0 (45.8) hours per week caring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Challenges in early and biomarker-based diagnosis were identified and care partners continued to experience a substantial burden. Continued efforts are needed to ensure the healthcare system's preparedness for the AD epidemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25424823261447853","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:56:41Z","timestamp":1780664201000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic journey, biomarker testing, treatment, and care partner burden in patients with mild cognitive impairment and Alzheimer's disease dementia in China: A real-world survey"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6794-1750","authenticated-orcid":false,"given":"Jiawei","family":"Xin","sequence":"first","affiliation":[{"name":"Fujian Medical University Union Hospital"},{"name":"Fujian Medical University"},{"name":"Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-6073","authenticated-orcid":false,"given":"Hanxi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Cai","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Li","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanshen","family":"Dou","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda Botello","family":"Estrada","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5643-6725","authenticated-orcid":false,"given":"Chloe","family":"Walker","sequence":"additional","affiliation":[{"name":"Adelphi Real World"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Storm","sequence":"additional","affiliation":[{"name":"Adelphi Real World"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Medical University Union Hospital"},{"name":"Fujian Medical University"},{"name":"Fujian Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2022-100751"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01382-x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07169-7"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afv020"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.131"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30290-X"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-025-00672-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33109-4"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12256-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.06.1892"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.37819\/hb.3.1771"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14263"},{"key":"e_1_3_3_15_2","unstructured":"Eisai Co. and Biogen. \u201cLEQEMBI\u00ae\u201d (Lecanemab) Approved for the Treatment of Alzheimer\u2019s Disease in China https:\/\/investors.biogen.com\/news-releases\/news-release-details\/leqembir-lecanemab-approved-treatment-alzheimers-disease-china (2024 accessed 26 February 2025)."},{"key":"e_1_3_3_16_2","unstructured":"Eli Lilly and Company. Lilly's Kisunla\u2122 (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-china-treatment-early (2024 accessed 26 February 2025)."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-015-0038-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06239-4"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2279679"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_3_3_24_2","unstructured":"EPHMRA. 2022 Code of conduct https:\/\/www.ephmra.org\/sites\/default\/files\/2022-08\/EPHMRA%202022%20Code%20of%20Conduct.pdf (2022 accessed 26 February 2025)."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251322978"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610219001856"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2017.05.012"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610215000940"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170370"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03991.x"},{"key":"e_1_3_3_31_2","unstructured":"Alzheimer's Disease International. World Alzheimer Report 2019 - Attitudes to dementia https:\/\/www.alzint.org\/u\/WorldAlzheimerReport2019.pdf (2019 accessed 26 February 2025)."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0609-7"},{"key":"e_1_3_3_33_2","first-page":"269","article-title":"Chinese Guideline for the diagnosis and treatment of Alzheimer's disease dementia (2020)","volume":"40","author":"Tian J","year":"2021","unstructured":"Tian J, Xie HG, Wang L, et al. Chinese Guideline for the diagnosis and treatment of Alzheimer's disease dementia (2020). Chin J Geriatr 2021; 40: 269\u2013283.","journal-title":"Chin J Geriatr"},{"key":"e_1_3_3_34_2","first-page":"3292","article-title":"Chinese Guideline for clinical application of fluid biomarkers for Alzheimer\u2019s disease (2024 edition)","volume":"104","author":"National Health Commission Capacity Building and Continuing Education Center; Chinese Neuroscience Society; Aging Biomarker Consortium; Writing Group for the Chinese Guideline for Clinical Application of Fluid Biomarkers for Alzheimer\u2019s Disease","year":"2024","unstructured":"National Health Commission Capacity Building and Continuing Education Center; Chinese Neuroscience Society; Aging Biomarker Consortium; Writing Group for the Chinese Guideline for Clinical Application of Fluid Biomarkers for Alzheimer\u2019s Disease. Chinese Guideline for clinical application of fluid biomarkers for Alzheimer\u2019s disease (2024 edition). Natl Med J China 2024; 104: 3292\u20133306.","journal-title":"Natl Med J China"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3233\/ADR230007"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029663"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13348"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-025-00836-y"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2013.02.010"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-024-01713-y"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1104250"},{"key":"e_1_3_3_42_2","unstructured":"Alzheimer's Disease International. Global estimates of informal care https:\/\/www.alzint.org\/u\/global-estimates-of-informal-care.pdf (2018 accessed 28 May 2025)."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2018.304573"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-14-6"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/13607863.2016.1146871"}],"container-title":["Journal of Alzheimer's Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261447853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25424823261447853","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25424823261447853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:56:44Z","timestamp":1780664204000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25424823261447853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["10.1177\/25424823261447853"],"URL":"https:\/\/doi.org\/10.1177\/25424823261447853","relation":{},"ISSN":["2542-4823","2542-4823"],"issn-type":[{"value":"2542-4823","type":"print"},{"value":"2542-4823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"25424823261447853"}}